IDH2 and central nervous system cancer: TMB for IDH mutant glioma is < 20 mutations/MB with the vast majority have TMB < 2 mutations/MB compared to PMMRDIA TMB of < 30 mutations/MB and MMR-deficient gliomas TMB between 80 and 380 mutations/MB (Wang et al., 2020).